A new multinational study from the INTERCOVID Consortium, including Ann & Robert H. Lurie Children’s Hospital of Chicago, has found that COVID-19 vaccination during pregnancy, particularly when combined with a booster dose, significantly reduces the risk of preeclampsia, a serious and potentially life-threatening pregnancy complication. The findings offer unprecedented insight into preeclampsia prevention, independent of the direct effects of COVID-19 infection.
The study, published in eClinicalMedicine , titled COVID-19 Vaccination Status During Pregnancy and Preeclampsia Risk: The Pandemic-Era Cohort of the INTERCOVID Consortium , analysed data from 6,527 pregnant women across 18 countries enrolled between 2020 and 2022. Researchers compared vaccinated and unvaccinated women, with and without SARS-CoV-2 infection, to assess how vaccination status influenced preeclampsia rates.
“Our results support the importance of strengthening COVID vaccination programs during pregnancy, emphasising boosters and ensuring that pregnant people across the world have equitable access to the vaccine,” said study co-author Jagjit S. Teji, MD , a neonatologist at Lurie Children’s and Clinical Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine. “We offer evidence from the first large study suggesting that COVID vaccination may protect against one of the most serious pregnancy complications.”
Key Findings
“These results go beyond the known benefits of COVID-19 vaccination in pregnancy,” said Professor José Villar , the senior co-author of the study and Principal Investigator of the INTERCOVID consortium from the Nuffield Department of Women’s & Reproductive Health, University of Oxford (UK) . “We now have evidence that maternal vaccination may influence pathways involved in preeclampsia development, suggesting a broader immunological or vascular benefit of vaccination.”
Preeclampsia affects up to 3%-8% of pregnancies worldwide, depending on the risk profile, and is a leading cause of maternal and neonatal morbidity and mortality. The origins of preeclampsia are unknown and treatments and preventive measures must be improved, but inflammation, and vascular dysfunction are known contributors, mechanisms that overlap with COVID-19 infection.
The INTERCOVID findings support the idea that vaccination may modulate immune and vascular pathways involved in preeclampsia, potentially offering protection even in the absence of COVID-19 infection. This aligns with growing evidence that some vaccines may have beneficial “non-specific” effects on immune regulation.
The INTERCOVID consortium includes over 40 hospitals across 18 countries, reflecting a truly global effort to understand maternal and perinatal outcomes during the pandemic.
Ann & Robert H. Lurie Children’s Hospital of Chicago is a nonprofit organization committed to providing access to exceptional care for every child. It is the only independent, research-driven children’s hospital in Illinois and one of less than 35 nationally. This is where the top doctors go to train, practice pediatric medicine, teach, advocate, research and stay up to date on the latest treatments. Exclusively focused on children, all Lurie Children’s resources are devoted to serving their needs. Research at Lurie Children’s is conducted through Stanley Manne Children’s Research Institute, which is focused on improving child health, transforming pediatric medicine and ensuring healthier futures through the relentless pursuit of knowledge. Lurie Children’s is the pediatric training ground for Northwestern University Feinberg School of Medicine. It is ranked as one of the nation’s top children’s hospitals by U.S. News & World Report .
EClinicalMedicine